Summary
▪ We augment the well-known susceptible – infected – recovered – deceased (SIRD) epidemiological model to include vaccination dynamics, implemented as a piecewise continuous simulation. We calibrate this model to reported case data in the UK at a national level,
▪ Our modelling approach decouples the inherent characteristics of the infection from the degree of human interaction (as defined by the effective reproduction number, Re). This allows us to detect and infer a change in the characteristic of the infection, for example the emergence of the Kent variant,
▪ We find that that the infection rate constant (k) increases by around 89% as a result of the B.1.1.7 (Kent) COVID-19 variant in England,
▪ Through retrospective analysis and modelling of early epidemic case data (between March 2020 and May 2020) we estimate that ∼1.2M COVID-19 infections were unreported in the early phase of the epidemic in the UK. We also obtain an estimate of the basic reproduction number as, R0 = 3.23,
▪ We use our model to assess the UK Government’s roadmap for easing the third national lockdown as a result of the current vaccination programme. To do this we use our estimated model parameters and a future forecast of the daily vaccination rates of the next few months,
▪ Our modelling predicts an increased number of daily cases as NPIs are lifted in May and June 2021,
▪ We quantify this increase in terms of the vaccine rollout rate and in particular the percentage vaccine uptake rate of eligible individuals, and show that a reduced take up of vaccination by eligible adults may lead to a significant increase in new infections.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No third party funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
None
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos